Bitcoin price today: surges to $122k, near record high on US regulatory cheer
LONDON - Autolus Therapeutics plc (NASDAQ:AUTL), a biopharmaceutical company specializing in T cell therapies for cancer, has announced its participation in the upcoming 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. The event, scheduled from February 12-15 in Honolulu, will feature an oral presentation and three poster presentations from Autolus, highlighting their latest findings on AUCATZYL®, their FDA-approved CAR-T cell therapy.
The company's oral presentation, delivered by Dr. Karamjeet S. Sandhu, will discuss risk factors associated with hematotoxicity in patients treated with AUCATZYL® for relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). The findings indicate that a pre-treatment risk stratification model may help identify patients who could benefit from the treatment with reduced toxicity.
One of the poster presentations will showcase a cost model comparing AUCATZYL® with other CAR-T cell therapies. The model, based on data from the FELIX and ZUMA-3 trials, suggests that AUCATZYL® may reduce healthcare costs due to lower rates and shorter durations of adverse events like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). This focus on cost-effectiveness comes as InvestingPro analysis shows impressive revenue growth of 82.7% over the last twelve months, though the company is currently trading near its 52-week low, suggesting potential value opportunity for investors. Get access to 13 additional ProTips and comprehensive financial analysis with an InvestingPro subscription.
Another poster will compare the effectiveness of AUCATZYL® against standard non-CAR-T therapies. The data, presented by Dr. Sandhu, demonstrates that AUCATZYL® leads to higher overall response rates and longer overall survival and event-free survival compared to the standard of care in matched external control arms, with comparable safety profiles.
The final poster, presented by Dr. Aaron C. Logan, will focus on the impact of deep molecular remissions on clinical outcomes. Among patients treated with AUCATZYL®, those achieving a measurable residual disease (MRD) of less than one in a million leukemic cells showed more durable responses and higher survival rates than those with higher MRD levels.
Autolus Therapeutics is known for developing, manufacturing, and delivering next-generation programmed T cell therapies. AUCATZYL® is their proprietary CD19-directed CAR T cell therapy, designed to minimize the activation of programmed T cells, potentially improving safety compared to existing CD19 CAR T therapies.
The press release statement from Autolus indicates that these presentations aim to provide further insights into the potential benefits of AUCATZYL® in treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. With analysts maintaining a strong buy consensus and the stock currently trading below its InvestingPro Fair Value, investors seeking detailed analysis can access the comprehensive Pro Research Report, available exclusively to subscribers, covering all aspects of Autolus's financial health and market position.
In other recent news, Autolus Therapeutics has reported several significant developments. The company's FELIX study, published in the New England Journal of Medicine, revealed a 76.6% complete remission rate in adult B-cell Acute Lymphoblastic Leukemia (ALL) patients treated with obecabtagene autoleucel (obe-cel), with a median follow-up of 20.3 months. Autolus also reported a strong financial position, with more cash than debt on its balance sheet and revenue growth of 83% in the last twelve months.
In addition, Autolus has received FDA approval for obe-cel, now named AUCATZYL, and the product is currently under review by European and UK regulators. Following these developments, Redburn-Atlantic upgraded Autolus's stock from Neutral to Buy, signaling confidence in the company's future. Despite reporting increased operating expenses and a net loss for the third quarter of 2024, the company maintains a substantial cash reserve of $657.1 million and anticipates future milestone payments and regulatory approvals.
These recent developments suggest that Autolus is positioned for expansion and could potentially outperform expectations. The company is expanding its treatment center network and advancing its pipeline with new studies and programs. Autolus also expressed optimism about the potential for outpatient administration of obe-cel and is on track for EU approval by mid-2025. These are the latest updates in the company's operations, providing a glimpse into its recent progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.